Amide Derivative Covalent Bonding Overcomes EGFR T790M Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drugs targeting EGFR tyrosine kinase, such as Gefitinib and Erlotinib, face challenges with drug resistance development, particularly the EGFR T790M mutation, limiting their effectiveness in treating cancer.
Innovation Solution
A novel amide derivative with a specific structural formula, including various aryl and heterocyclic groups, is developed to selectively inhibit EGFR tyrosine kinase, potentially overcoming resistance by forming a covalent bond with Cysteine 773, thereby irreversibly blocking autophosphorylation and inhibiting cancer cell growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If reversible inhibitors (Gefitinib, Erlotinib) are used to inhibit EGFR, then EGFR activity is inhibited, but drug resistance develops due to EGFR T790M mutation
Solution Approach 1:
The patent changes the binding mechanism parameter from reversible to irreversible by introducing an acrylamide group that forms a covalent bond with Cysteine 773 of EGFR. This parameter change transforms the drug's interaction mode with the target, enabling sustained inhibition that prevents resistance development while maintaining effective EGFR inhibition.
Solution Approach 2:
The patent creates a composite molecular structure combining the quinazoline core (for ATP binding) with an acrylamide substituent (for covalent bonding). This composite structure integrates both reversible binding capabilities and irreversible covalent attachment, achieving dual functionality that overcomes drug resistance while maintaining target specificity.
2Reliability
If irreversible inhibitors with acrylamide substituent are used, then drug resistance is prevented, but selectivity against EGFR must be maintained
Solution Approach 1:
The patent applies local quality by positioning the reactive acrylamide group specifically at the 6-position of the quinazoline ring, which corresponds to the ATP binding site of EGFR. This localized placement ensures that the irreversible bonding occurs only at the intended target site, maintaining selectivity while achieving resistance prevention. The rest of the molecule retains properties optimized for EGFR specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amide derivative effectively inhibits cancer cell growth induced by EGFR overexpression and prevents drug resistance, offering enhanced anticancer effects, including improved inhibition of EGFR tyrosine kinase mutants with minimal adverse side effects.
Implementation Method 1
potentially overcoming resistance by forming a covalent bond with Cysteine 773, thereby irreversibly blocking autophosphorylation and inhibiting cancer cell growth
Data Source
AI summary
The present invention provides a novel amide derivative and a pharmaceutically acceptable salt thereof which selectively and effectively inhibits the growth of cancer cells induced by the overexpression of an epidermal growth factor receptor and also prevents the development of drug resistance caused by the mutation of EGFR tyrosine kinase, and a pharmaceutical composition comprising same as an active ingredient.